Several small- and mid-cap biotech and medical stocks saw notable after-hours price action on Friday, September 26, following a mix of clinical updates, investor presentations, and strategic announcements.Enanta Pharmaceuticals Inc. (ENTA) surged sharply in after-hours trading on Friday, September 26, following a modest gain during the regular session. The stock closed the day at $7.90, up 1.94%, before vaulting another 20% after hours to reach $9.48. This dramatic post-close rally was driven by investor r ...

Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced the continued expansion of its commercial footprint in the Middle East, following the first succes ...

Core Viewpoint - Nyxoah has filed a patent infringement lawsuit against Inspire Medical Systems, claiming that Inspire's devices infringe on three of its patents related to Obstructive Sleep Apnea treatment [1] Group 1: Company Overview - Nyxoah is a medical technology company focused on innovative solutions for treating Obstructive Sleep Apnea (OSA) [3] - The company's lead product is the Genio system, which is a leadless and battery-free hypoglossal neurostimulation therapy for OSA [3] - Nyxoah aims to provide patients with restful nights and improve their quality of life [3] Group 2: Product and Market Position - The Genio system received its European CE Mark in 2019 and has recently gained FDA approval as a prescription-only device in August 2025 [4][5] - The company has completed two successful IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021 [4] - Positive outcomes from clinical studies, including the BETTER SLEEP study and the DREAM IDE pivotal study, have supported the expansion of therapeutic indications for the Genio system [4] Group 3: Legal Action - The lawsuit against Inspire Medical Systems was filed in the United States District Court for the District of Delaware, seeking injunctive relief and damages for patent infringement [1] - The patents in question are U.S. Patent Nos. 8,700,183, 9,415,215, and 9,415,216 [1] Group 4: Leadership and Commitment - Olivier Taelman, CEO of Nyxoah, emphasized the company's commitment to defending its intellectual property and providing a differentiated solution for OSA treatment [2] - The company has received positive feedback from physicians and patients following the U.S. commercial launch of the Genio system [2]

Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 2025 Wells Fargo Healthcare ConferenceSeptember 3rd – Boston, MA Cantor Global Healthcare Conference 2025 September 4 ...

Company Overview - Nyxoah (NYXH) received FDA approval for its Genio system, an innovative therapy for moderate to severe Obstructive Sleep Apnea (OSA) featuring a leadless, battery-free design powered by an upgradable wearable [1][8] - The Genio system utilizes a unique bilateral nerve stimulation approach, now launching in the U.S. market [1][3] Clinical Trial Results - The FDA approval was supported by the DREAM pivotal trial, which achieved a 63.5% apnea-hypopnea index (AHI) responder rate and a 71.3% Oxygen Desaturation Index (ODI) responder rate, with a median AHI reduction of 70.8% [4] - Notably, 82% of participants saw their AHI drop below 15, demonstrating Genio's efficacy across all sleeping positions [4][5] Product Features - Genio's design is MRI compatible (1.5T and 3T), making it more convenient and less invasive for patients [3] - The system is powered and controlled by a wearable component, which is fully upgradable, allowing for technology updates without additional surgeries or battery replacements [3][5] Market Prospects - The global sleep apnea devices market was estimated at $4.5 billion in 2023 and is projected to reach $6.9 billion by 2030, with a CAGR of 6.2% from 2024 to 2030 [6] - Key growth drivers include a growing geriatric population, a significant patient pool with sleep apnea, and the development of advanced devices [6] Competitive Landscape - Nyxoah competes with several innovative players in the sleep apnea treatment market, including Inspire Medical Systems, ResMed, and LivaNova, all of which are developing advanced therapies and devices [7][10][11] - Inspire Medical Systems launched its Inspire V neurostimulation system, which features a 20% reduction in implant time and Bluetooth-enabled connectivity [7][9] - ResMed introduced its AirSense 11 CPAP device with advanced capabilities to enhance patient adherence and clinician access [10] - LivaNova reported a 65% responder rate in its OSPREY trial for its aura6000 proximal hypoglossal nerve stimulator, indicating sustained efficacy [11]

Core Viewpoint - Nyxoah has reported preliminary financial results for Q2 2025, indicating significant growth and successful commercial proof of concept in Germany, with plans to expand into the U.S. market following FDA approval of its Genio system [1][3]. Financial Results - Revenue for Q2 2025 is anticipated to be approximately €1.3 million, representing a 73% increase compared to Q2 2024 [4]. - Operating expenses for Q2 2025 are expected to be around €20.7 million, a 50% increase from Q2 2024 [4]. - Cash, cash equivalents, and financial assets are projected to be approximately €43.0 million as of June 30, 2025 [4]. Business Updates - The Genio system has received FDA approval for a subset of adult patients with moderate to severe Obstructive Sleep Apnea (OSA), specifically those with an Apnea-Hypopnea Index (AHI) between 15 and 65 [4][6]. - The company plans to close patient enrollment in its ACCCESS clinical trial, which aims to assess the safety and efficacy of Genio therapy for patients suffering from Complete Concentric Collapse (CCC) [4]. - Nyxoah has reorganized its global R&D function, transitioning ongoing activities from Israel to the U.S. and Belgium [4]. Legal Matters - Inspire Medical Systems, Inc. has filed a lawsuit against Nyxoah in the U.S. for alleged patent infringement, and the company intends to vigorously defend itself [4].